AstraZeneca PLC Block listing Interim Review

Date : 12/02/2019 @ 3:00PM
Source : UK Regulatory (RNS & others)
Stock : Astrazeneca Plc (AZN)
Quote : 7697.0  46.0 (0.60%) @ 12:11PM
Astrazeneca share price Chart

AstraZeneca PLC Block listing Interim Review

Astrazeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Astrazeneca Charts.

TIDMAZN

RNS Number : 3770V

AstraZeneca PLC

02 December 2019

02 December 2019 15:00 GMT

Block Listing Six Monthly Return

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 2 December 2019

 
 Name of applicant:                                  ASTRAZENECA PLC 
 Name of scheme:                                     ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE 
                                                     OPTION PLAN; ASTRAZENECA 
                                                     ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED 
                                                     SHARE OPTION SCHEME 
                                                    ------------------------------------------------------------------ 
 Period of return:          From:                    1 June 2019                To:            30 November 2019 
                           -----------------------  -------------------------  -------------  ------------------------ 
 Balance of unallotted securities under scheme(s) 
  from previous return:                              1,248,036 
                                                    ------------------------------------------------------------------ 
 Plus: The amount by which the block scheme(s) has 
  been increased since the date of the last 
  return (if any increase has been applied for):     0 
                                                    ------------------------------------------------------------------ 
 Less: Number of securities issued/allotted under 
  scheme(s) during period (see LR3.5.7G):            136,370 
                                                    ------------------------------------------------------------------ 
 Equals: Balance under scheme(s) not yet 
  issued/allotted at end of period:                  1,111,666 
                                                    ------------------------------------------------------------------ 
 
 
 
 Name of contact:                CAMILLA JOHNSTONE 
 Telephone number of contact:    020 3749 5000 
                                ------------------ 
 

About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 
 Media Relations 
 Gonzalo Viña                                                                                    +44 203 749 5916 
 Rob Skelding                           Oncology                                                      +44 203 749 5821 
 Rebecca Einhorn                        Oncology                                                       +1 301 518 4122 
 Matt Kent                              BioPharmaceuticals                                            +44 203 749 5906 
 Jennifer Hursit                        Other                                                         +44 203 749 5762 
 Christina Malmberg Hägerstrand    Sweden                                                        +46 8 552 53 106 
 Michele Meixell                        US                                                             +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                                                  +44 203 749 5712 
 Henry Wheeler                          Oncology                                                      +44 203 749 5797 
 Christer Gruvris                       BioPharmaceuticals (Cardiovascular, Metabolism)               +44 203 749 5711 
                                        BioPharmaceuticals (Renal) Environmental, Social and 
 Nick Stone                              Governance                                                   +44 203 749 5716 
                                        BioPharmaceuticals (Respiratory) 
 Josie Afolabi                           Other medicines                                              +44 203 749 5631 
                                        Finance 
 Craig Marks                             Fixed income                                                 +44 7881 615 764 
                                        Corporate access 
 Jennifer Kretzmann                      Retail investors                                             +44 203 749 5824 
 US toll-free                                                                                         +1 866 381 72 77 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BLRFSEFLEFUSEDE

(END) Dow Jones Newswires

December 02, 2019 10:00 ET (15:00 GMT)

Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200129 12:26:17